Fig. 2
From: Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study
Outcome measures monitored during treatment with dupilumab or methotrexate in adults with atopic dermatitis. a Eczema Area Severity Index (EASI), b Patient-Oriented Eczema Measure (POEM), c Pruritus Visual Analogue Scale Score (VAS, 0–10 cm), d Dermatology Life Quality Index (DLQI), e Montgomery-Åsberg Depression Rating Scale (MADRS). Dupilumab (DUP) in gray (n = 12) and methotrexate (MTX) in red (n = 8)